Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis

Table 2

Demographic and clinical characteristics of included studies for new-onset MHA after transcatheter ASDC.

Study	Country	Design	Patients	Mean age (yr)	Treatments		Sample size	Dropouts	Efficacy results	Adverse events
					Intervention	Control
Kato et al. [13]	Japan	Retrospective observational study	Patients underwent ASDC with or without migraine	27	Clopidogrel, ticlopidine, aspirin+ticlopidine, and ticlopidine+warfarin following ASDC for 6 months	Aspirin, asprin+warfarin, and dipyridamole+warfarin following ASDC for 6 months	50 vs. 157	NA	New-onset MHA occurred in 23 (11%) patients (4 vs. 19)	NA
Rodés-Cabau et al. [14]	Canada	Parallel RCT	Patients with an indication for ASDC and no history of migraine	49	Aspirin 80 mg/d+clopidogrel 75 mg/d following ASDC for 3 months	Aspirin 80 mg/d+placebo for 3 months	84 vs. 87	16 vs. 16	New-onset MHA occurred in 27 (16%) patients (8 vs. 19). Number of monthly migraine days: 0.4 vs. 1.4 days); difference: -1.02 (95% CI, -1.94 to -0.10)	Total: 14 vs. 19; Major bleeding: 0; Minor bleeding: 5 vs. 1
Wilmshurst et al. [15]	UK	Retrospective observational study	Patients underwent ASDC with or without migraine	39.6	Aspirin 150-300 mg/d for six months+clopidogrel 75 mg/d for the first month	Aspirin 150-300 mg/d for 6 months	90 vs. 71	NA	New-onset MHA occurred in 12 (7%) patients (3 vs. 9)	Major bleeding: 1; Gastrointestinal haemorrhage and 1 pelvic haematoma in aspirin+clopidogrel group

RCT: randomized controlled trial; NA: not applicable; ASDC: atrial septal defect closure; MHA: migraine headache.